Key Drivers
- Strong liquidity
- Severe cash burn
- High valuation
AIAI Summary
Agios has transitioned from a speculative R&D biotech to an early‑commercial, cash‑backed specialty pharma whose near‑term valuation will be decided by mitapivat's US payer uptake and upcoming sickle‑cell/tebapivat readouts—monitor commercial ramp metrics, any REMS/label constraints, and securities investigations as the specific triggers that will drive re‑rating or force dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Severe cash burn
- •High valuation
AGIO has a strong balance sheet and low leverage but is burning large cash and reporting steep losses while trading at a high valuation.
Price Behavior
Key Price Behavior Insights:
- •Lower-highs forming
- •Multiple support tests
- •Range-bound trading
Over the last month AGIO has drifted down ~4.8% to $27.86, trading ~3% below its 21-day MA (~$28.70) with support near $27.40 holding and resistance at $30.20–$30.40—break below support implies further weakness while a break above resistance would signal a reversal.
Moderate 8–9% high-to-low swing over the period, limiting rapid moves
Sentiment & News
Key News Insights:
- •Regulatory win
- •Clinical setbacks
- •Legal scrutiny
Agios scored UAE approval for PYRUKYND but offset that win with mixed Phase III data, an FDA delay, a 23% six‑month stock decline and multiple securities‑law probes despite an activist stake increase.
The combination of clinical/regulatory uncertainty and active litigation risks will likely keep Agios shares volatile and pressured near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings